AT A recent meeting of the American Heart Association in New Orleans, researchers report that a safer and
better alternative to aspirin has been manufactured to inhibit heart attacks and strokes. The new blood thinner called clopidogrel was tested by a Canadian team of researchers on more than 19,000 people in 16 countries,
who had suffered heart attacks, strokes or pain from clogged arteries in their legs.
Subjects were required to take aspirin or clopidogrel for periods ranging from one to three years. The tests revealed there were 5.8 new heart attacks, strokes or deaths from cardio-vascular disease annually for every 100 patients taking aspirin, compared to 5.3 for those taking the new drug. The mechanism by which clopidogrel works, is similar to aspirin's; inhibiting platelets which form blood clots though in a different manner. The plus point is that it has fewer side effects. Patients taking the drug were less likely to suffer from gastrointestinal bleeding, compared to those taking aspirin.
The new blood thinner is expected to be costlier than aspirin.
We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.
Comments are moderated and will be published only after the site moderator’s approval. Please use a genuine email ID and provide your name. Selected comments may also be used in the ‘Letters’ section of the Down To Earth print edition.